MS Australia's advocacy team is regularly looking for opportunities to contribute to policy development and government reviews.
MS Australia Submissions:
Note: (1) : joint submission with MS
(2) : joint submission with MS Research Australia
(3) : joint submission with Neurological Alliance Australia (NAA)
(4) : joint submission with Assistive Technology for All Alliance (ATFA)
2021
- NDIS consultation: Support for decision making
- NDIS consultation: An Ordinary Life at Home
- Senate Community Affairs References Committee Inquiry into the Purpose, intent and adequacy of the Disability Support Pension
- Pre-budget submission for the 2021-2022 Federal Budget
- Joint Standing Committee on the NDIS inquiry into independent assessments under the NDIS
- NAA submission to Independent Assessments inquiry (3)
- NDIS consultation on Access and eligibility policy with independent assessments
- NDIS consultation on Planning policy for personalised budgets and plan flexibility
- Response from Minister Stuart Robert regarding NDIS Independent assessment letter
- Department of Social Services consultation on the Disability Employment Strategy
2020
- Letter to Minister Stuart Robert regarding NDIS Independent assessment
- Report on the Impact of the intro of Independent Assessment on People with MS
- NDIS Review of Support Coordination
- Joint Standing Committee on the NDIS inquiry into the NDIS Quality and Safeguards Commission
- NDIS Consultation on Supported Independent Living
- Inquiry into approval processes for new drugs and novel medical technologies in Australia (2)
- Disability Royal Commission (Rights & Attitudes Issues Paper) (4)
- Therapeutic Goods Administration Consultation: Proposed amendments to the Poisons Standard regarding cannabidiol (2)
- Victorian State Disability Plan 2021-2024 Consultation (4)
- NDIS Workforce
2019
- Pre-budget Submission (4)
- Senate inquiry into barriers to access to medicinal cannabis (2)
- ATFA submission to the Royal Commission into Aged Care Quality and Safety, December 2019 (4)
- NAA submission to the Royal Commission into Aged Care Quality and Safety, August 2019 (3)
- NDIS Planning
- NDIS Supported Independent Living
- NDIS Thin Markets Project
- Royal Commission into Aged Care Quality & Safety
- Streamlined Consumer Assessment for Aged Care
2018
- My Health Record
- Assistive Technology in the NDIS (1)
- Qld Parliament Medicinal Cannabis Act (2)
- Senate Select Committee Inquiry on Charity Fundraising
- Implementation of the NDIS in NSW (1)
- Vic Government Draft Disability Action Plan 2018-2020 (1)
- Regulation of mobility scooters
- Implementation of the NDIS in the ACT (1)
2017
- Transitional Arrangements for NDIS
- NAA position paper on Productivity Commission’s Review of NDIS Costs (with cover letter) (3)
- Productivity Commission NDIS Costs
- NDIS 2017 Price Controls Review
- Medicinal Cannabis Affordability Bill - Qld (2)
- DIRD Consultation on The Whole Journey Guide
- Delivery of Outcomes under the National Disability Strategy 2010-2020
- Secondary use of My Health Record Data
- Superannuation Assessing Efficiency and Competitiveness
- Victorian Disability Workforce
2016
- Continuity of Support program
- Pharmacy Remuneration and Regulation
- New Disability Employment Services from 2018
- ILC Commissioning framework
- Election Commitments: Submission to the major parties for the 2016 Federal Election (2)
- Vic State Disability Plan 2017-2020 (1)
- Submission to the NDIS inquiry into accommodation for people with disabilities and the NDIS
- Submission to TGA re Poisons Standard for Medicinal Cannabis (2)
- Inquiry into the Public Health (Medicinal Cannabis) Bill - Qld (2)
- Services for people with psychosocial disabilities
2015
- MS Australia Willing to Work Submission
- NDIS Quality and Safeguard Framework Submission
- Victorian Law Reform Commission's Medicinal Cannabis Issues Paper (2)
- NDIS Information, Linkages and Capacity Building (ILC) Policy Framework
- Senate Legal and Constitutional Affairs Legislation Committee Inquiry- Medicinal Cannabis Bill (2)
- Young people in res care inquiry
- Cannabis Use for Medical Purposes ACT bill (2)
- TGA Regulations Stem Cells Submission
- Disability Advocacy Framework consultation
- Increasing choice in home care Stage 1
- New aged care short-term restorative care program
2014
- McClure Welfare Review Submission
- Airline two wheelchair policy
- Federal Senate Inquiry - Out-of-pocket health costs
2013
MS Australia Submissions to the Pharmaceutical Benefits Advisory Committee:
One area of advocacy we are particularly passionate about is advocating for greater access to affordable treatments for people with MS. MSA and MS Research Australia work together closely on treatment and research advocacy. No two cases of MS are the same and there is no one size fits all treatment for the disease. MS Australia regularly makes submissions supporting the listing of MS treatments on the Pharmaceutical Benefits Scheme (PBS) so that people with MS and their neurologists have greater choice and flexibility to find the treatment method that best suits them. The research and medication information contained in these submissions is provided by MS Research Australia.
2021
2020
- Eculizumab (Soliris ®) for NMOSD – joint submission with MS Research Australia and the Centre for Community-Driven Research
- Ocrelizumab (Ocrevus®) for Primary Preogressive MS – July 2020 PBAC Review
- Nabiximols (Sativex®) for spasticity in MS - March 2020 PBAC Review
- Ozanimod (Zeposia®) for Relapsing Remitting MS (RRMS) - March 2020 PBAC Review
- Siponimod (Mayzent®) for Secondary Progressive MS (SPMS) - March 2020 PBAC Review
2019
- Fingolimod (Gilenya) for under 40kg - July 2019 PBAC Review
- Natalizumab (Tysabri) for all ages - July 2019 PBAC Review
2018
- Cladribine (MAVENCLAD) for RRMS re-submission – July PBAC Review
- Cladribine (MAVENCLAD) for RRMS re-submission – March PBAC Review
2017
- Glatiramer acetate (Copaxone) for Clinically Isolated Syndrome - PBAC Review
- Clabribine (MAVENCLAD) for RRMS - PBAC Review
- Ocrelizumab (Ocrevus) for RRMS - PBAC Review
- Ocrelizumab (Ocrevus) for PPMS - PBAC Review
2016
2015
2014
- Expressed Authority - PBAC Review
- Fampridine (Fampyra) - PBAC Review
- Alemtuzumab (Lemtrada) - PBAC Review
- Alemtuzumab (Lemtrada) (additional) - PBAC Review
- Peginterferon beta-1a (Plegridy) - PBAC Review
2013